

*Gnosis by Lesaffre unveils new website dedicated to **ibSium**[®],
breakthrough beneficial live yeast probiotic supporting complete
intestinal comfort*

For immediate release, April 2019 – Gnosis by Lesaffre, the business unit of Lesaffre dedicated to human health and nutrition (and the result of the merger between Lesaffre Human Care and Gnosis), is raising awareness about **ibSium**[®] with the launch of a website dedicated to its patented proprietary solution. The company developed this format as a way to expand their reach and increase **ibSium**[®]'s visibility worldwide.

“This website was designed with the user experience in mind and offers a clean layout, simple navigation and a way for users to contact us with ease, directly from the page. We are inviting visitors to explore it and to discover the numerous benefits of **ibSium**[®] for intestinal health, as well as learn more about the substantial scientific evidence behind this unique strain of *Saccharomyces cerevisiae*”, explains Elodie Ruffin, Probiotics Product Manager at Gnosis by Lesaffre.

Elodie Ruffin expects the new site, found at www.ibsium.com, to be of interest for product developers and ingredients purchasers, as it offers detailed information about the ingredient itself, as well as clinical data and practical advice on how to use it to alleviate occasional intestinal pain, bloating and constipation.

With Gnosis by Lesaffre’s strong emphasis on providing world-class scientific and clinical data on its solutions, this new website is also a way for visitors to stay informed about the latest research results and peer-review publications about **ibSium**[®].

What is **ibSium[®]?**

ibSium[®] is the brand name of *Saccharomyces cerevisiae* CNCM I-3856, an exclusive strain of yeast probiotic patented by Lesaffre. This innovative ingredient is used in a wide range of dietary supplements developed by the company’s partners since 2010 and already widely prescribed by doctors and gastroenterologists.

Endorsed by consumers, **ibSium**[®] is a breakthrough in digestive health. The science around this ingredient supporting intestinal comfort, shows it may improve the quality of life of billions of people worldwide, who suffer from painful digestive disorders or complain about gut-related symptoms.

ibSium[®] has indeed demonstrated that it may relieve intestinal pain, bloating and constipation in several clinical studies^{1,2} and the findings of a meta-analysis investigating **ibSium**[®]'s health benefits, published in the renowned peer-reviewed journal ‘World Journal of Gastroenterology’³. A large-scale study run by prescribing physicians in over 1160 volunteers presenting symptoms of IBS has also proven **ibSium**[®] to be safe, fast-acting (less than 15 days) and well-tolerated, inducing no side-effects or habituation.

Therefore, **ibSium**[®] can be considered as an innovative solution of natural origin designed to alleviate occasional intestinal pain and discomfort.

###

For questions about *ibSium*[®] or its new website, feel free to contact us through the online form found at <https://ibsium.com/#contact>; or visit www.gnosisbylesaffre.com for information about any of Gnosis by Lesaffre's health-promoting solutions.

About Gnosis by Lesaffre

Gnosis by Lesaffre is a business unit of Lesaffre, a world expert in fermentation, dedicated to human health and nutrition. The company aspires to be a trusted innovation partner for its clients to assist them in helping consumers lead healthier and happier lives. Gnosis by Lesaffre develops and supplies innovative solutions and ingredients of natural origin with scientifically proven efficacy to meet the expectations of consumers all over the world to support their digestive health, immunity enhancement, women's health, joints and liver health, mood management, vegetarian and day-to-day nutrition...

For further information, visit www.gnosisbylesaffre.com

¹ Pineton de Chambrun G, Neut C, Chau A, Cazaubiel M, Pelerin F, Justen P, Desreumaux P. *A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome*. Digestive and Liver Disease; 2015 February; 47(2):119-124

² Spiller RS, Pélerin F, Cayzele Decherf A, Maudet C, Housez B, Cazaubiel M, Justen P. *Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in Irritable Bowel Syndrome: improvement in abdominal pain and bloating in those with predominant constipation*. United European Gastroenterology Journal, published online before print August 21, 2015.

³ Cayzele-Decherf A, Pélerin F, Leuillet S, Douillard B, Housez B, Cazaubiel M, Jacobson GK, Jüsten P, Desreumaux P. *Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: an individual subject meta-analysis*. World J Gastroenterol 2017;23(2):336-344.